Peter J. Ruane, M.D. Report issue

Academic/Hospital Phase 2 Phase 4

Organization Overview

First Clinical Trial
2008
NCT00751153
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

Peter J. Ruane, M.D., Inc. | Peter J. Ruane, MD, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Autoimmune Diseases (Phase 4)

Hepatitis (Phase 2)

Hepatitis A (Phase 2)

Hepatitis C (Phase 4)

Hepatitis C, Chronic (Phase 4)

HIV Infections (Phase 4)

Virus Diseases (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 4
  • # of Trial APIs: 6